International Conference on Lymphocyte Engineering (ICLE) 2018

International Conference on Lymphocyte Engineering (ICLE) is organized by Kenes Group and will be held from Sep 13 - 15, 2018 at Melia Avenida America, Madrid, Spain.

The theme of ICLE is Advancing immuno-gene therapy across diseases, emphasising the need for combined efforts of a dedicated community to realize the full promise of lymphocyte engineering.

The clinical translation and treatment in immuno-gene therapy. ICLE brings together immunotherapy with cell and gene therapy to foster interdisciplinary collaborations, deepening the connection between basic and clinical research across related disease specialties: oncology, pathogenic diseases, autoimmunity, immunodeficiencies and others. With unprecedented success from more than 200 clinical trials, the recent increase in investment funding, and FDA approvals, lymphocyte engineering has a potentially significant role in the future of healthcare. Whether you are a scientist, clinical researcher, part of a start-up or an established industry company, ICLE 2018 will be your opportunity to network and discuss immuno-gene therapy with those as excited and passionate about the future as you.

Programme highlights include :

• Lymphocyte engineering for the treatment of Hematological malignancies
• Lymphocyte engineering for the treatment of Solid tumors
• Genome editing for allogeneic ACT
• Safety switches & controlled expression
• Engineering HSC, NK, NKT and ?? T cells
• Target & receptor discovery
• Lymphocyte engineering for the treatment of HIV
• Optimizing receptor and vector design
• Non viral vectors and transposons

Whether you are a scientist, clinical researcher, part of a start-up or an established industry company, ICLE 2018 is your opportunity to network and discuss immuno-gene therapy with those as excited and passionate about this innovative treatment modality as you.

Why Attend :

• Participate in the only event that merges all the exciting breakthroughs under one conference - gene therapy, cell therapy, genome engineering, and immunotherapy.
• Gain access to quality networking with colleagues advancing related knowledge across diseases.
• Meet the thought leaders, who will share invaluable insights on CAR-T Cell and other lymphocyte engineering therapies.
• Present your research, clinical findings, therapies and pipeline to a focused international audience.
• Become part of the only community dedicated to lymphocyte engineering.

* Abstract Submission Deadline: 23 May 2018
* Early Registration Deadline: 19 June 2018

Speakers :

* Malcolm Brenner,
* Adi Barzel,
* Thomas Blankenstein,
* Christian Buchholz,
* Dirk Busch,
* Laurence Cooper,
* Michael Hudecek,
* Anjelica Loskog,
* Daniel Powell,
* Waseem Qasim,
* Axel Schambach,
* Andrew Scharenberg,
* Wolfgang Uckert,
* Paula Cannon,
* Cyrille Cohen,
* Zelig Eshhar,
* Dinorah Friedmann-Morvinski,
* Stephen Gottschalk,
* Aya Jakobovits,
* Carl June,
* Bruce Levine,
* Marcela Maus,
*Dan Peer,
* Mattew Porteus,
* Barbara Savoldo

Additional details will be posted as soon as they are available.